Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Pacini, F ^a   Castagna, M G ^a   Brilli, L ^a   Pentheroudakis, G ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; IODINE 131; RECOMBINANT THYROTROPIN; THYROTROPIN;

ARTICLE; ASPIRATION BIOPSY; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; DIFFERENTIAL DIAGNOSIS; DRUG DOSE COMPARISON; ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPOPARATHYROIDISM; LARYNGEAL NERVE; LYMPH NODE METASTASIS; NERVE PARALYSIS; PATIENT SAFETY; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; SENSITIVITY AND SPECIFICITY; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA;

DIAGNOSIS, DIFFERENTIAL; EUROPE; FOLLOW-UP STUDIES; HEALTH PLANNING GUIDELINES; HUMANS; SOCIETIES, MEDICAL; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 66549094590     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp156     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Leenhardt L, Bernier MO, Boin-Pineau MH et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol 2004; 150: 133-139.
3. Levi F, Randimbison L, Te VC et al. Thyroid cancer in Vaud, Switzerland: an update. Thyroid 2002; 12: 163-168.
4. Pacini F, Burroni L, Ciuoli C et al. Management of thyroid nodules: A clinicopathological evidence-based approach. Eur J Nucl Med Mol Imaging 2004; 31: 1443-1449.
5. Cap J, Ryska A, Rehorkova P et al. Sensitivity and specificity of the fine needle aspiration biopsy of the thyroid: Clinical point of view. Clin Endocrinol 1999; 51: 509-515.
6. Pacini F, Schlumberger M, Dralle H et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.
7. Cooper DS, Doherty GM, Haugen BR et al. The American Thyroid Association Guidelines Taskforce Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 109-142.
8. Elisei R, Bottici V, Luchetti F et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: Experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004; 89: 163-168.
9. Pacini F, Ladenson PW, Schlumberger M et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study. J Clin Endocrinol 2006; 91: 926-932.
10. Pilli T, Brianzoni E, Capoccetti F et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92: 3542-3546.
11. Wittekind C, Compton CC, Greene FL et al. TNM residual tumor classification revisited. Cancer 2002; 94: 2511-2516.
12. Mazzaferri EL, Jhiang SM. Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-428.
13. Schlumberger M, Borget I, De Pouvourville G et al. Recombinant human thyroid-stimulating hormone: Use in papillary and follicular thyroid cancer. Horm Res 2007; 67 (Suppl 1): 132-142.
14. Pacini F, Capezzone M, Elisei R et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002; 87: 1499-1501.
15. Cailleux AF, Baudin E, Travagli JP et al. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000; 85: 175-178.
16. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: A reassessment. Nat Clin Pract Endocrinol Metab 2005; 1: 32-40.
17. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005; 90: 5047-5057.
18. Castagna MG, Brilli L, Pilli T et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 2008; 93: 76-81.
19. Iervasi A, Iervasi G, Ferdeghini M et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol 2007; 67: 434-441.
20. Smallridge RC, Meek SE, Morgan MA et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007; 92: 82-87.
21. Schlumberger M, Hitzel A, Toubert ME et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 2007; 92: 2487-2495.
22. Pacini F, Cetani F, Miccoli P et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg 1994; 18: 600-604.
23. Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91: 2892-2899.
24. Pennell NA, Daniels GH, Haddad RI et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008; 18: 317-323.
25. Sherman SI, Schlumberger M, Doz J et al. Initial results from a phase II trial of motesanib diphosphote (AMG 706) in patients with differentiated thyroid cancer. Forty-third Annual Meeting of the American Society of Clinical Oncology (ASCO 2007), June 1-4, Chicago, IL.
26. Wells SA, Gosnell JE, Gagel RF et al. Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase III trial. Forty-third Annual Meeting of the American Society of Clinical Oncology (ASCO 2007), June 1-4, Chicago, IL (Abstr 6018).